Praziquantel

Parasitology Research

Volumn 90, Issue SUPPL.1, 2003, Pages

  Cioli, Donato ^a   Pica Mattoccia, Livia ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; PRAZIQUANTEL;

ABDOMINAL PAIN; ANOREXIA; ANTIPROTOZOAL ACTIVITY; CLINICAL PRACTICE; DIARRHEA; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; EPIGASTRIC PAIN; FEVER; HEADACHE; HISTORY OF MEDICINE; HUMAN; INSOMNIA; LASSITUDE; MYALGIA; NAUSEA; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA INTERCALATUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; VERTIGO; VOMITING;

SCHISTOSOMA; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA INTERCALATUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI;

EID: 0037963682     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-002-0751-z     Document Type: Review

References (86)

1. Andrews P (1981) A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Drug Res 31:538-541
2. Andrews P, Thomas H, Pohlke R, Seubert J (1983) Praziquantel. Med Res Rev 3:147-200
3. Anwar WA (1994) Praziquantel (antischistosomal drug): is it clastogenic, co-clastogenic or anticlastogenic? Mutat Res 305:165-173
4. Anwar WA, Rosin MP (1993) Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantel. Mutat Res 298:179-185
5. Anwar WA, Au WW, Ramanujam VMS, Legator MS (1989) Enhancement of benzene clastogenicity by praziquantel in mice. Mutat Res 222:283-289
6. Appleton C, Mbaye A (2001) Praziquantel - quality, dosages and markers of resistance. Trends Parasitol 17:356-357
7. Bale JFJr (2000) Cysticercosis. Curr Treat Options Neurol 2:355-360
8. Bassily S, Farid Z, Dunn M, El-Masry NA, Stek MJr (1985) Praziquantel for treatment of schistosomiasis in patients with advanced splenomegaly. Ann Trop Med Parasitol 79:629-634
9. Becker B, Mehlhorn H, Andrews P, Thomas H, Eckert J (1980) Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 63:113-128
10. Bennett JL, Day T, Feng-Tao L, Ismail M, Farghaly A (1997) The development of resistance to anthelmintics: a perspective with an emphasis on the antischistosomal drug praziquantel. Exp Parasitol 87:260-267
11. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, Gemetchu T (1999) Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 72:53-63
12. Bouree P (1991) Successful treatment of Taenia saginata and Hymenolepis nana by single oral dose of praziquantel. J Egypt Soc Parasitol 21:303-307
13. Brindley PJ, Strand M, Norden AP, Sher A (1989) Role of host antibody in the chemotherapeutic action of praziquantel against Schistosoma mansoni: identification of target antigens. Mol Biochem Parasitol 34:99-108
14. Castro N, Medina R, Sotelo J, Jung H (2000) Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 44:2903-2904
15. Cioli D (2000) Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13:659-663
16. Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R, Diaz-de-Liano A, Ciga MA (1998) Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health 3:462-466
17. Davis A, Biles JE, Ulrich AM (1979). Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ 57:773-779
18. Day TA, Bennett JL, Pax RA (1992) Praziquantel: the enigmatic antiparasitic. Parasitol Today 8:342-344
19. De Clercq D, Vercruysse J, Verle P, Kongs A, Diop M (2000) What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop Med Int Health 5:744-746
20. Doenhoff MJ, Sabah AAA, Fletcher C, Webbe G, Bain J (1987) Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans R Soc Trop Med Hyg 81:947-951
21. Doenhoff MJ, Kimani G, Cioli D (2000) Praziquantel and the control of schistosomiasis. Parasitol Today 16:364-366
22. Doenhoff MJ, Kusel JR, Coles GC, Cioli D (2002) Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg (in press)
23. El Guiniady MA, El Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A (1994) Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 51:809-818
24. Fallon PG, Doenhoff MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 51:83-88
25. Fallon PG, Sturrock RF, Capron A, Niang M, Doenhoff MJ (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg 53:61-62
26. Farid Z, Mansour N, Kamal K, Girgis N, Woody J, Kamal M (1987) The diagnosis and treatment of acute toxaemic schistosomiasis in children. Trans R Soc Trop Med Hyg 81:959
27. Foster R (1987) A review of clinical experience with oxamniquine. Trans R Soc Trop Med Hyg 81:55-59
28. Frohberg H (1984) Results of toxicological studies on praziquantel. Arzneimittelforschung 34:1137-1144
29. Giorgi M, Salvatori AP, Soldani G, Giusiani M, Longo V, Gervasi PG, Mengozzi G (2001) Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica. J Vet Pharmacol Ther 24:251-259
30. Gönnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd 52:129-150
31. Gryseels B, Stelma FF, Talla I, van Dam GJ, Polman K, Sow S, Diaw M, Sturrock RF, Doehring-Schwerdtfeger E, Kardoff R, Decam C, Niang M, Deelder AM (1994) Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 46:209-219
32. Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guisse F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuente LA, Engels D, Polman K (2001) Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6:864-873
33. Hall A, Nokes C, Wen ST, Adjei S, Kihamia C, Mwanri L, Bobrow E, de Graft-Johnson J, Bundy D (1999) Alternatives to body-weight for estimating the dose of praziquantel needed to treat schistosomiasis. Trans R Soc Trop Med Hyg 93:653-658
34. Harnett W, Kusel JR (1986) Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology 93:401-405
35. Harries AD, Cook GC (1987) Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy. J Infect 14:159-161
36. Herrera LA, Ostrosky-Wegman P, Montero R, Rojas E, Gonsebatt ME, Schiffmann D (1994) Evaluation of the carcinogenic and genotoxic potential of praziquantel in the Syrian hamster embryo cell transformation assay. Mutat Res 305:175-180
37. Homeida M, Leahy W, Copeland S, Ali MM, Harron DW (1994) Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol 88:551-559
38. Ishizaki T, Kamo E, Boehme K (1979) Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. Bull World Health Organ 57:787-791
39. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL (1996) Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55:214-218
40. Ismail M, Botros S, Metwally A, William S, Farghally A, Tao LF, Day TA, Bennett JL (1999) Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60:932-935
41. Jaoko WG, Muchemi G, Oguya FO (1996) Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East Afr Med J 73:499-501
42. Jung H, Medina R, Castro N, Corona T, Sotelo J (1997) Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother 41:1256-1259
43. Katz N, Rocha R, Chaves A (1979) Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull World Health Organ 57:781-785
44. Kohn AB, Anderson PAV, Roberts-Misterly JM, Greenberg RM (2001) Schistosome calcium channel β subunits: unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. J Biol Chem 276:36873-36876
45. Kramers PGN, Gentile JM, Gryseels BJM, Jordan P, Katz N, Mott KE, Mulvihill JJ, Seed JL, Frohberg H (1991) Review of the genotoxicity and carcinogenicity of antischistosomal drugs; is there a case for a study of mutation epidemiology? Report of a task group on mutagenic antischistosomals. Mutat Res 257:49-89
46. Kusel J, Hagan P (1999) Praziquantel - its use, cost and possible development of resistance. Parasitol Today 15:352-354
47. Leopold G, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DH (1978) Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14:281-91
48. Lerch C, Blaschke G (1998) Investigation of the stereoselective metabolism of praziquantel after incubation with rat liver microsomes by capillary electrophoresis and liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 708:267-275
49. Liang YS, Coles GC, Doenhoff MJ, Southgate VR (2001) In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel. Int J Parasitol 31:1227-1235
50. Liu YH, Qian MX, Wang XG, Jia J, Wang QN, Jiang YF, Wang RQ, Yan SW, Chen BY, Li JS, Qiu ZY, Shen JK (1986) Comparative efficacy of praziquantel and its optic isomers in experimental therapy of schistosomiasis japonica in rabbits. Chin Med J 99:935-940
51. Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW (1990) Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389-393
52. Masimirembwa CM, Hasler JA (1994) Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors. Biochem Pharmacol 48:1779-1783
53. Masimirembwa CM, Naik YS, Hasler JA (1994) The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans. Biopharm Drug Dispos 15:33-43
54. Mehlhorn H, Becker B, Andrews P, Thomas H, Frenkel JK (1981) In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. Drug Res 31:544-554
55. Meier H, Blaschke G (2001) Investigation of praziquantel metabolism in isolated rat hepatocytes. J Pharm Biomed Anal 26:409-415
56. Metwally A, Bennett JL, Botros S, Ebeid F (1995) Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel. Drug Res 45:516-518
57. Monson MH (1987) Praziquantel in acute schistosomiasis. Trans R Soc Trop Med Hyg 81:777
58. Montero R, Ostrosky P (1997) Genotoxic activity of praziquantel. Mutat Res 387:123-139
59. Montero R, Flisser A, Madrazo I, Cuevas C, Ostrosky-Wegman P (1994) Mutation at the HPRT locus in patients with neurocysticercosis treated with praziquantel. Mutat Res 305:181-188
60. Montresor A, Engels D, Chitsulo L, Bundy DA, Brooker S, Savioli L (2001) Development and validation of a "tablet pole" for the administration of praziquantel in sub-Saharan Africa. Trans R Soc Trop Med Hyg 95:1-3
61. Na-Bangchang K, Vanijanonta S, Karbwang J (1995)Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone. Southeast Asian J Trop Med Public Health 26:120-123
62. Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, Peters P, McGarvey S, Odhiambo O, Koech D, Liu CY, Aligui G, Gachihi G, Kombe Y, Parraga I, Ramirez B, Whalen C, Horton RJ, Reeve P (1999) Double-blind, placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis 179:996-1003
63. Overbosch D (1992) Neurocysticercosis. An introduction with special emphasis on new developments in pharmacotherapy. Schweiz Med Wochenschr 122:893-898
64. Pax R, Bennett JL, Fetterer R (1978) A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum. Naunyn-Schiedbergs Arch Pharmacol 304:309-315
65. Polderman AM, Gryseels B, Gerold JL, Mpamila K, Manshande JP (1984) Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg 78:752-754
66. Renganathan E, Cioli D (1998) An international initiative on praziquantel use. Parasitol Today 14:390-391
67. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ (1986) Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 61:294-303
68. Scrimgeour EM, Gajdusek DC (1985) Involvement of the central nervous system in Schistosoma mansoni and Schistosoma haematobium infection. Brain 108:1023-1038
69. Seubert J, Pohlke R, Loebich F (1977) Synthesis and properties of praziquantel, a novel broad spectrum anthelminthic with excellent activity against schistosomes and cestodes. Experientia 33:1036-1037
70. Sotelo J, Jung H (1998) Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 34:503-515
71. Staudt U, Schmahl G, Blaschke G, Mehlhorn H (1992) Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro. Parasitol Res 78:392-397
72. Steiner K, Garbe A, Diekmann HW, Novak H (1976) The fate of praziquantel in the organism. I: Pharmacokinetics in animals. Eur J Drug Metab Pharmacokinet 1:85-95
73. Stelma FF, Talla A, Sow S, Kongs A, Niang M, Polman K, Deelder AM, Gryseels B (1995) Efficacy and side-effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53:167-170
74. Stelma FF, Sall S, Daff B, Sow S, Niang M, Gryseels B (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 176:304-307
75. Sulaiman SM, Traoré M, Engels D, Hagan P, Cioli D (2001) Counterfeit praziquantel. Lancet 358:666-667
76. Thomas H, Gönnert R. (1977) The efficacy of praziquantel against cestodes in animals. Z Parasitenkd 52:117-127
77. Utzinger J, Chollet J, Jiqing Y, Jinyan M, Tanner M, Shuhua X (2001) Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop 80:9-18
78. Valencia CI, Catto BA, Webster LTJr, Barcelon E, Ofendo-Reyes R (1994) Concentration time course of praziquantel in Filipinos with mild Schistosoma japonicum infection. Southeast Asian J Trop Med Public Health 25:409-414
79. Watt G, Adapon B, Long GW, Fernando MT, Ranoa CP, Cross JH (1986) Praziquantel in treatment of cerebral schistosomiasis. Lancet 2:529-532
80. Webbe G, James C (1977) A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei in hamsters. Z Parasitenkd 52:169-177
81. Wegner DHG (1984) The profile of the trematodicidal compound praziquantel. Arzneimittelforschung 34:1132-1136
82. Westhoff F, Blaschke G (1992) High-performance liquid chromatographic determination of the stereoselective biotransformation of the chiral drug praziquantel. J Chromatogr 578:265-271
83. World Health Organisation (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis. First report of the joint World Health Organisation Expert Committees, World Health Organisation, Geneva (in press)
84. Wu MH, Wei, CC, Xu Z, Yuan HC, Lian WN, Yang QJ, Chen M, Jiang QW, Wang CZ, Zhang SJ (1991) Comparison of the therapeutic efficacy and side effects of a single dose of levopraziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. Am J Trop Med Hyg 45:345-349
85. Xiao SH, Catto BA (1989) Comparative in vitro and in vivo activity of racemic praziquantel and its levorotated isomer on Schistosoma mansoni. J Infect Dis 159:589-592
86. Xiao SH, Catto BA, Webster LT (1985) Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis 151:1130-1137